Britain and America have reached a major commercial pact that will maintain no import taxes on British pharmaceutical products being sold in the American market.
Agreement Details of the Pact
As part of the deal, the UK has committed to boost expenditure on pharmaceuticals through the National Health Service (NHS). This commitment secures that duties on these key products will stay at nothing for a period of 36 months.
This agreement comes after previous threats to dramatically increase tariffs on patented drug products, with increases mentioned reaching one hundred percent.
"This arrangement between the United Kingdom bolsters the global environment for innovative medicines and establishes much-needed equity to transatlantic drug exports," an announcement said.
Trade Importance
Pharmaceuticals are one of the UK's biggest export categories to the US, which is clearly the primary buyer for major British pharmaceutical firms.
Trade data reveal that in the 12 months prior to September, the UK shipped drugs valued at £11.1bn to the US. This value made up 17.4% of British export trade in that timeframe.
"This deal protects work, boosts funding and paves the way for the UK to establish itself as a worldwide center for life sciences," a minister stated.
Specific NHS Changes
The deal includes several specific changes from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the price threshold at which it judges new medicines to be too expensive by a quarter.
- Higher Drug Budget: There is a target to double overall health service expenditure on medicines from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The amount manufacturers must return to the NHS to prevent overspending will be restricted at 15%. In the past, rebates exceeded twenty percent.
Broader Context
The deal comes amid a protracted tension between the drug companies and the ministers over medicine costs and NHS adoption.
These tensions were exacerbated by claims that US consumers were charged several times more for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several significant drug company projects in the UK have been paused or scrapped, while substantial investments have been pledged toward projects in the United States.
One official publicly accepted that the NHS had to increase expenditure on drugs, noting that its spending on drugs had decreased as a share of its total funding over the previous ten-year period.
